$144 Million to Treat Aging Itself: Inside ARPA-H's PROSPR Program and What It Means for Health Research Funding

The federal government just placed a $144 million bet that aging is treatable — and that proving it doesn't require waiting decades for someone to die or not die.

ARPA-H's PROactive Solutions for Prolonging Resilience (PROSPR) program, which announced its seven funded research teams in late February, represents something the U.S. government has never attempted at this scale: clinical trials designed to show within one to three years whether an intervention can measurably slow human aging. Not a specific disease. Not a single organ system. Aging itself — the biological process that makes every other disease more likely.

The program is built on a deceptively simple insight. If researchers can identify biomarkers that respond to aging interventions within months rather than years, they can run clinical trials that produce actionable data on human timelines instead of epidemiological ones. PROSPR's seven teams are each attacking a different piece of that problem, from repurposing FDA-approved drugs to building entirely new scoring systems for biological age. Together, they constitute the most concentrated federal investment in human longevity research ever awarded outside the National Institute on Aging — and they're structured as contracts, not grants, with milestone-based payments that can be cut if teams don't deliver.

As Granted News reported, ARPA-H secured $1.5 billion in FY2026 appropriations and is increasingly positioning itself as the primary federal agency for longevity and chronic disease research. PROSPR is the sharpest expression of that pivot.

Seven Teams, Seven Bets on the Biology of Aging

The program's structure reveals ARPA-H's hedging strategy. Rather than backing a single theory of aging, the agency distributed up to $144 million across seven teams pursuing fundamentally different approaches.

UT Health San Antonio received up to $38 million — the program's largest single award — for its VITAL-H trial, which will test three FDA-approved drugs in generally healthy adults aged 60 to 65. The drugs are rapamycin (an immunosuppressant that has extended lifespan in every animal model tested), dapagliflozin (an SGLT2 inhibitor originally developed for diabetes), and semaglutide (the active ingredient in Ozempic and Wegovy). Each operates through a distinct biological mechanism. The trial recruits from South Texas, deliberately targeting a population that reflects projected U.S. demographic patterns, and uses wearable technology to monitor participants' "Intrinsic Capacity" — a composite measure of cognition, mobility, psychological function, vitality, and sensory function.

Stanford University is taking a data-first approach, harmonizing massive institutional health datasets to generate a predictive healthspan score. Rather than testing drugs, Stanford's team is building the measurement infrastructure PROSPR needs — defining what "biological aging" looks like in quantitative terms and validating those metrics through a one-year lifestyle intervention study using digital health technology. If PROSPR's drug trials show that rapamycin or semaglutide slows aging, Stanford's work determines how we know.

Brown University and the University of Rochester share an award of up to $22 million to test a drug called Censavudine (TPN-101), originally developed for HIV, on a mechanism most people have never heard of: retrotransposons. These are fragments of ancient viral DNA embedded in the human genome that become increasingly active with age, triggering immune responses that mimic viral infections and drive chronic inflammation. Brown's John Sedivy has spent 15 years demonstrating this mechanism in the lab. PROSPR funds the first human clinical trial — 200 healthy adults aged 60 to 65, randomized to drug or placebo for 48 weeks, across three clinical sites including UConn Health and the University of Texas Medical Branch.

Cambrian BioPharma received up to $30.8 million to test a next-generation rapamycin analog — a daily oral compound designed to selectively inhibit mTORC1, the specific molecular target that mediates rapamycin's longevity effects in animal models, without the immunosuppressive side effects that make standard rapamycin problematic for long-term use. If successful, it would be the first purpose-built longevity drug to complete human trials.

Columbia University's Mailman School of Public Health is mining previously completed clinical trials to identify which biomarkers respond earliest to interventions that improve long-term health outcomes. This is the meta-analytical backbone of the program — turning decades of accumulated trial data into a roadmap for what to measure in future aging studies.

Linnaeus Therapeutics received up to $22 million to test LNS8801, a compound targeting the GPER receptor, translating findings from over 100 oncology trial patients into healthspan preservation applications. Apollo Alpha rounds out the seven with a compound targeting energy homeostasis, lipid metabolism, and inflammation — the metabolic triad that deteriorates most consistently with age.

Why Contracts Instead of Grants

PROSPR's structure as milestone-based contracts rather than traditional NIH-style grants is not incidental. ARPA-H operates under DARPA's model: program managers set aggressive timelines, define measurable deliverables, and retain the authority to redirect or terminate funding if teams fail to hit milestones. This is a fundamentally different relationship between funder and researcher than the R01 grant mechanism that dominates biomedical science.

For research organizations, the implications are practical. PROSPR contracts require teams to demonstrate progress against defined endpoints on compressed timelines — one to three years for biomarker validation, not the five-to-seven-year cycles typical of NIH-funded longitudinal studies. Teams that miss milestones lose funding. Teams that exceed them may receive additional resources.

This structure favors organizations with existing clinical trial infrastructure, established IRB relationships, and the operational capacity to recruit and monitor trial participants quickly. It disadvantages early-stage academic labs that typically use federal grants to build capacity over time. The seven PROSPR awardees all have either significant clinical trial experience (UT Health San Antonio, Brown, Columbia) or venture-backed operational teams (Cambrian, Linnaeus, Apollo Alpha).

ARPA-H's Strategic Pivot and What It Signals

ARPA-H was created in 2022 with a broad mandate to pursue "high-potential, high-impact biomedical and health research." Under the Biden administration, its early focus centered heavily on cancer. Under the current administration, with HHS Secretary Robert F. Kennedy Jr. reshaping health agency priorities, ARPA-H has pivoted sharply toward chronic disease and longevity — a shift that extends well beyond PROSPR.

The agency recently terminated three programs focused on hospital cybersecurity, AI for medical imaging, and preventive care, while simultaneously doubling down on aging biology. It laid off at least 15 employees in the same week it secured its $1.5 billion FY2026 allocation, suggesting internal restructuring to align staffing with the new strategic direction.

For grant seekers, the signal is clear: ARPA-H's chronic disease and longevity focus is not a temporary emphasis — it reflects the agency's institutional direction under current leadership. Organizations working in aging biology, healthspan extension, biomarker development, or chronic disease prevention are operating in the most favorable federal funding environment for longevity research in U.S. history.

The Biomarker Problem — and Why It's the Real Prize

PROSPR's most consequential output may not be any single drug trial. It may be the biomarker validation work being done by Stanford, Columbia, and embedded within each of the drug trials.

The fundamental obstacle to longevity research has never been a shortage of promising interventions. Rapamycin extends lifespan in mice. Caloric restriction extends lifespan in virtually every organism tested. Metformin appears to reduce all-cause mortality in diabetic populations. The obstacle is measurement: proving that an intervention slows aging in humans requires either waiting 30 years to count deaths or developing surrogate endpoints that regulators accept as proxies for long-term benefit.

PROSPR is attacking this measurement problem directly. If the program succeeds in validating biomarkers that respond to aging interventions within one to three years — blood markers, functional capacity scores, digital health metrics from wearables — it creates a regulatory pathway for every future longevity intervention. That pathway would transform aging research from a scientific curiosity funded by eccentric billionaires into a clinical discipline with FDA-approvable endpoints and, eventually, reimbursable treatments.

The commercial implications are enormous. The longevity biotech sector has attracted billions in private capital — Cambrian BioPharma alone has raised over $100 million from private investors — but has been fundamentally constrained by the absence of regulatory endpoints for "aging" as a treatable condition. PROSPR's biomarker work could unlock the regulatory framework that makes longevity drugs commercially viable.

What Grant Seekers Should Do Now

PROSPR itself is fully awarded — the seven contracts are signed and funded. But the program creates downstream opportunities across multiple funding channels.

For academic researchers: PROSPR's biomarker validation work will generate publicly available datasets and validated endpoint measures. Researchers who build on these outputs — studying the mechanisms behind PROSPR's biomarkers, extending the findings to underrepresented populations, or developing next-generation measurement tools — will find receptive program officers at both ARPA-H and the National Institute on Aging. NIA's budget remains over $4 billion annually, and PROSPR's results will shape NIA's funding priorities for the next decade.

For biotech companies: The SBIR/STTR programs at both ARPA-H and NIH fund small businesses developing health technologies. Companies building digital health tools for aging assessment, biomarker measurement platforms, or decentralized clinical trial infrastructure are directly aligned with PROSPR's technical needs. The recently reauthorized SBIR/STTR programs include new Strategic Breakthrough Awards of up to $30 million for companies that have completed Phase II and can demonstrate commercial viability.

For health systems and clinical trial networks: PROSPR's emphasis on decentralized, in-home trial designs creates demand for organizations that can recruit and monitor clinical trial participants outside traditional academic medical centers. Health systems serving diverse populations — particularly those in underrepresented geographies — should watch for future ARPA-H solicitations building on PROSPR's infrastructure.

For digital health and wearable companies: Stanford's PROSPR component explicitly uses digital health technology for remote monitoring and healthspan assessment. The $34.5 million THRIVE program, also funded by ARPA-H, is developing the first FDA-grade "Intrinsic Capacity" score using wearable data, with WHOOP among the commercial partners. Companies with wearable platforms, remote patient monitoring capabilities, or AI-driven health analytics should position for this growing intersection of consumer technology and federally funded aging research.

The federal government has decided that aging is a treatable condition and committed $144 million to prove it. Whether PROSPR's trials succeed or fail, the biomarker infrastructure they create will reshape how longevity research is funded, regulated, and commercialized for decades — and Granted can help you identify the specific funding opportunities emerging from this shift before the next solicitation cycle closes.